Neumirna Therapeutics is pleased to welcome Ina Brünig-Traebert as Chief Development Officer. As an experienced neuroscientist, Ina brings over two decades of experience in drug development at leading global pharmaceutical companies including Roche and Novartis. Here she has led cross-functional development teams across a broad range of therapeutic areas.
Most recently, Ina led the global development of Rugonersen at Roche. Rugonersen is an RNA-based therapy for the rare neurodevelopmental disorder Angelman Syndrome. Originally developed in Copenhagen and later acquired by Roche, the program progressed under Ina’s leadership through the early stages of clinical development until Phase 3-ready. Recently, the program became part of the pipeline at Boston-based Oak Hill Bio.
"With a highly relevant background in RNA-based therapies for complex neurological disorders, Ina is an ideal match for Neumirna," said Janine Erler, CEO of Neumirna. "Her experience in bringing forward innovative programs like Rugonersen gives us great confidence as we move into clinical development."
A return to RNA innovation in Copenhagen
"The moment I heard about Neumirna, it felt like a match," Ina said." Having previously led the development of a program that originated in Copenhagen, it’s incredibly meaningful to now be part of a company carrying that same spirit of innovation forward. It truly feels like a full-circle moment."
As Chief Development Officer, Ina will lead the advancement of NMT-001, Neumirna’s lead ASO-LNA candidate for drug-resistant epilepsy, as well as its follow-on candidates in the company’s growing clinical pipeline. Her initial focus will be on strengthening and refining a high-performing, cross-functional development team to support Neumirna’s transition into clinical-stage development.
"What excites me most about Neumirna’s approach is the promise of true disease modification," Ina said. "These are not ordinary development programs, they hold the potential to finally address the unmet need of patients living with devastating neurological conditions."
Ina brings her strategic guidance and clinical development expertise to the company at a pivotal stage of growth. With her leadership, Neumirna is well-positioned to advance its pipeline and bring meaningful therapies to patients in need.
.svg)
